ClinicalTrials.gg
CompletedNCT04783090Updated Jul 29, 2022

MT1013 Clinical TRIAL In Healthy Subject

A Phase 1 interventional study of MT1013 in Healthy Volunteer, sponsored by Shaanxi Micot Technology Limited Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-29.

Sponsored by Shaanxi Micot Technology Limited Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, single ascending dose administration phase one clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of MT1013 injection in healthy subjects.

Read the detailed description

This will be a single center, Phase 1, randomized, double-blind single-dose, sequential SAD study.

This SAD study will consist of up to 5 cohorts (1 cohort per dose level). Each cohort will include 8 subjects (6 subjects receiving the active study drug and 2 subjects receiving matching placebo).

A staggered dosing schedule will be used for each dose level administered under fasting conditions. Two (2) sentinel subjects (1 active and 1 placebo) will be dosed first (a minimum of 1 hour apart) and the remaining 6 subjects will be dosed no sooner than the next day (each dosed at least 15 minutes apart).

Following completion of each dose level, a SRC will review the safety and tolerability data as well as the available PK data up to 48 hours in order to make decisions whether to escalate to the next dose level, decrease the next dose level, repeat a dose level, or to not evaluate any additional dose.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Shaanxi Micot Technology Limited Company is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), ≥18 and ≤55 years of age, with >18.0 and \<30.0 kg/m2 and body weight ≥45.0 kg for males and females.
  2. Healthy as defined by:

    1. the absence of illness and surgery within 4 weeks prior to dosing.
    2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, GI, renal, hepatic, and metabolic disease.
  3. Females of who are sexually active with a non-sterile male partner must be willing to use one of the following acceptable methods throughout the study and for 30 days after the last study drug administration:
  4. Capable of consent.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for , , , or Treponema pallidum antibody found during medical screening.
  2. Positive urine drug screen or urine cotinine test or alcohol breath test at screening.
  3. Positive fecal occult blood test at screening.
  4. History of clinically significant drug allergies.
  5. Positive pregnancy test at screening.
  6. Clinically significant abnormalities ( ≥450 ms) or a family history of long QT syndrome.
  7. Clinically significant vital sign abnormalities at screening.
  8. History of significant alcohol abuse within 1 year prior to screening.
  9. History of significant drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
  10. Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days or 5 half-lives (whichever is longer) prior to the first dosing.
  11. Use of prohibited medications for the timeframes specified.
  12. Donation of plasma within 7 days prior to dosing.
  13. Breast-feeding subject.
  14. The combination of diseases that may affect the assessment of drug absorption, distribution, metabolism, excretion and safety data, or that can reduce compliance.
  15. Subjects with previous clinically significant history of epileptic seizures.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    1st cohort

    MT1013 injection at 2.5 mg.

    Drug: MT1013

  • Experimental
    2nd cohort

    MT1013 injection at 5 mg.

    Drug: MT1013

  • Experimental
    3rd cohort

    MT1013 injection at 10 mg.

    Drug: MT1013

  • Experimental
    4th cohort

    MT1013 injection at 15 mg.

    Drug: MT1013

  • Experimental
    5th cohort

    MT1013 injection at 20 mg.

    Drug: MT1013

Interventions

  • DrugMT1013

    bispecific peptide as a CaSR agonist and a functional OGP analogue

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of MT1013 for injection in healthy adult subjects.

    Assessment of adverse events

    Time frame: Three months

Secondary outcomes

  1. To characterize the pharmacokinetics (PK) of MT1013 for injection in healthy adult subjects

    AUC0-t

    Time frame: 3 days

  2. PK

    AUC0-inf

    Time frame: 3 days

  3. PK

    Cmax

    Time frame: 3 days

  4. PK

    Tmax

    Time frame: 3 days

  5. PK

    T½ el

    Time frame: 3 days

  6. To characterize the pharmacodynamics (PD) of MT1013 for injection in healthy adult subjects

    Serum PTH value

    Time frame: 3 days

  7. PD

    Serum total calcium value

    Time frame: 3 days

  8. PD

    serum phosphorous value

    Time frame: 3 days

07

Study locations

1 site
  • WCCT Global, Inc.
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Dec 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2021
First posted
Mar 5, 2021
StartActual
Jun 28, 2021
Primary completionActual
Dec 31, 2021
CompletionActual
Mar 17, 2022
Last update
Jul 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04783090
Lead sponsor
Shaanxi Micot Technology Limited Company
Collaborators
WCCT Global
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
Jun 28, 2021
Primary completion
Dec 31, 2021
Completion
Mar 17, 2022
Last update
Jul 29, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MT1013

Start the discussion